基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
揭示 SET：探索卵巢高级别浆液性癌及其 BRCA1/2 免疫表达
英文原题：Unraveling SET: Exploring ovarian high-grade serous carcinoma and its BRCA1/2 immunoexpression.
查看英文原题
Unraveling SET: Exploring ovarian high-grade serous carcinoma and its BRCA1/2 immunoexpression.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
BRCA1 的免疫组化分析是检测 BRCA1 功能异常的一种有效且可替代的方法，并且可以与 HGSC 的组织形态学模式相关联。
研究思路结论见上方概要
背景
BRCA1和BRCA2（乳腺癌1型和2型易感蛋白抗体）功能障碍常见于卵巢高级别浆液性癌（HGSC），通常由胚系突变、体细胞突变和启动子甲基化引起。识别具有BRCA缺陷的肿瘤具有治疗和预后意义。
方法
我们的目的是评估卵巢HGSC中实性、假子宫内膜样和移行细胞（SET）成分的临床病理特征及意义，并将其与BRCA1和2免疫表达进行关联。
结果
在评估的45例HGSC病例中，64.4%（29/45）的病例可见SET生长模式。此外，全部病例中有35.5%（16/45）显示BRCA1缺失，17.7%（8/45）的病例显示BRCA2缺失。TIL（肿瘤浸润淋巴细胞）（TILs）、坏死、淋巴血管侵犯和BRCA1缺失与SET模式形态呈正相关。
展开英文摘要原文
MATERIALS AND METHODS
Our goal was to assess the clinicopathological characteristics and significance of solid, pseudoendometrioid, and transitional (SET) ovarian HGSC and to correlate these with BRCA1 and 2 immunoexpression. RESULT: Of the total 45 HGSC cases assessed, SET growth pattern was seen in 64.4% (29/45) cases. Furthermore, 35.5% (16/45) of the total cases showed BRCA1 loss, and 17.7% (8/45) cases showed BRCA2 loss. Tumor-infiltrating lymphocytes (TILs), necrosis, lymphovascular invasion, and BRCA1 loss positively correlated with SET pattern morphology.
CONCLUSION
Immunohistochemical analysis for BRCA1 is an effective and alternative method for the detection of BRCA1 dysfunction and can be correlated with the histomorphological pattern of HGSC.
论文信息
- 作者
- Chaturvedi A、Mallya V、Mandal S、Mala YM
- 第一作者单位
- Department of Pathology, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India.India
- 通讯作者单位
- Department of Obstetrics and Gynaecology, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India.India
- 期刊
- Indian journal of pathology & microbiology2025 Jul 1
- 原文标识
- PubMed 40405589 · DOI 10.4103/ijpm.ijpm_575_24